



Universiteit
Leiden
The Netherlands

Randomized phase III study of docetaxel versus docetaxel plus intercalated erlotinib in patients with relapsed non-squamous non-small cell lung carcinoma

Steendam, C.M.J.; Peric, R.; Walree, N.C. van; Youssef, M.; Schramel, F.M.N.H.; Brocken, P.; ... ; NVALT Study Grp

Citation

Steendam, C. M. J., Peric, R., Walree, N. C. van, Youssef, M., Schramel, F. M. N. H., Brocken, P., ... Aerts, J. G. J. V. (2021). Randomized phase III study of docetaxel versus docetaxel plus intercalated erlotinib in patients with relapsed non-squamous non-small cell lung carcinoma. *Lung Cancer*, 160, 44-49. doi:10.1016/j.lungcan.2021.08.002

Version: Publisher's Version

License: [Creative Commons CC BY 4.0 license](https://creativecommons.org/licenses/by/4.0/)

Downloaded from: <https://hdl.handle.net/1887/3274092>

Note: To cite this publication please use the final published version (if applicable).



Randomized phase III study of docetaxel versus docetaxel plus intercalated erlotinib in patients with relapsed non-squamous non-small cell lung carcinoma

Christi M.J. Steendam^{a,b}, Robert Peric^a, Nico C. van Walree^b, Magdolen Youssef^c, Franz M.N. H. Schramel^d, Pepijn Brocken^e, John W.G. van Putten^f, Vincent van der Noort^g, G. D. Marijn Veerman^h, Stijn L.W. Koolen^{h,i}, Harry J.M. Groen^j, Anne-Marie C. Dingemans^{a,k}, Ron H.J. Mathijssenⁱ, Egbert F. Smit^{l,m}, Joachim G.J.V. Aerts^{a,*}, On behalf of the NVALT Study Group

^a Department of Pulmonary Diseases, Erasmus MC Cancer Institute, University Medical Center Rotterdam, Dr. Molewaterplein 40, 3015 GD, the Netherlands

^b Department of Pulmonary Diseases, Amphia Hospital Breda, Molengracht 21, 4818 CK, the Netherlands

^c Department of Pulmonary Diseases, Máxima Medical Center Veldhoven, De Run 4600, 5504 DB, the Netherlands

^d Department of Pulmonary Diseases, Antonius Hospital Nieuwegein, Koekoekslaan 1, 3435 CM, the Netherlands

^e Department of Pulmonary Diseases, Haga Hospital The Hague, Els Borst-Eilersplein 275, 2545 AA, the Netherlands

^f Department of Pulmonary Diseases, Martini Hospital Groningen, Van Swietenplein 1, 9728 NT, the Netherlands

^g Department of Biometrics, Netherlands Cancer Institute –Antoni van Leeuwenhoek Amsterdam, Plesmanlaan 121, 1066 CX, the Netherlands

^h Department of Medical Oncology, Erasmus MC Cancer Institute, University Medical Center Rotterdam, Dr. Molewaterplein 40, 3015 GD, the Netherlands

ⁱ Department of Hospital Pharmacy, Erasmus MC Cancer Institute, University Medical Center Rotterdam, Dr. Molewaterplein 40, 3015 GD, the Netherlands

^j Department of Pulmonary Diseases, University Medical Center Groningen and University of Groningen, Hanzeplein 1, 9713 GZ, the Netherlands

^k Department of Pulmonary Diseases, Maastricht University Medical Center, P. Debyelaan 25, 6229 HX Maastricht, the Netherlands

^l Department of Pulmonary Diseases, Netherlands Cancer Institute –Antoni van Leeuwenhoek, Plesmanlaan 121, 1066 CX Amsterdam, the Netherlands

^m Department of Pulmonary Diseases, Leiden University Medical Center, Albinusdreef 2, 2333 ZA, the Netherlands

ARTICLE INFO

Keywords:

Non-small-cell lung cancer

Docetaxel

Erlotinib

ABSTRACT

Background: Earlier preclinical and phase II research showed enhanced effect of docetaxel plus intercalated erlotinib. The NVALT-18 phase III study was designed to compare docetaxel with docetaxel plus intercalated erlotinib in relapsed metastasized non-squamous (NSQ) non-small cell lung cancer (NSCLC).

Methods: Patients with relapsed Epidermal Growth Factor Receptor (EGFR) wild type (WT) NSQ-NSCLC were randomized 1:1 to docetaxel 75 mg/m² intravenously on day 1 every 21 days (control), or docetaxel 75 mg/m² intravenously on day 1 plus erlotinib 150 mg/day orally on day 2–16 every 21 days (experimental arm). Progression free survival (PFS) was the primary endpoint, secondary objectives were duration of response, overall survival (OS) and toxicity.

Results: Between October 2016 and April 2018 a total of 45 patients were randomized and received treatment in the control ($N = 23$) or experimental arm ($N = 22$), the study was stopped due to slow accrual. Median PFS was 4.0 months (95% CI: 1.5–7.1) versus 1.9 months (95% CI 1.4–3.5), $p = 0.01$ respectively; adjusted hazard ratio (HR) 2.51 (95% CI: 1.16–5.43). Corresponding median OS was 10.6 months (95% CI: 7.0–8.6) versus 4.7 months (95% CI: 3.2–8.6), $p = 0.004$, with an adjusted HR of 3.67 (95% CI: 1.46–9.27). Toxicity was higher with combination therapy, with toxicity \geq CTCAE grade 3 in $N = 6$ (26%) in the control arm and $N = 17$ (77%) in the experimental arm ($p < 0.001$), mainly consisting of gastrointestinal symptoms and leukopenia.

Conclusions: Our study shows detrimental effects of docetaxel plus intercalated erlotinib, and strongly discourages further exploration of this combination in clinical practice.

* Corresponding author at: Department of Pulmonary Diseases, Erasmus MC Cancer Institute, University Medical Center Rotterdam, Dr. Molewaterplein 40, 3015 GD Rotterdam, the Netherlands.

E-mail address: j.aerts@erasmusmc.nl (J.G.J.V. Aerts).

<https://doi.org/10.1016/j.lungcan.2021.08.002>

Received 27 May 2021; Received in revised form 28 July 2021; Accepted 1 August 2021

Available online 4 August 2021

0169-5002/© 2021 The Authors. Published by Elsevier B.V. This is an open access article under the CC BY license (<http://creativecommons.org/licenses/by/4.0/>).

1. Introduction

During the last decade the treatment paradigm for metastatic or locally advanced non-small cell lung carcinoma (NSCLC) has improved dramatically, with the introduction of immunotherapy with or without chemotherapy as first line regimen [1].

This poses a great challenge for patients progressing during or shortly after this first line of treatment. In those patients with non-squamous (NSQ) NSCLC treated with pemetrexed chemotherapy in first line, only docetaxel is left as the approved second line treatment [1].

Although erlotinib, a first generation Epidermal Growth Factor Receptor (EGFR) tyrosine kinase inhibitor (TKI), is approved for second or third line treatment, it is rarely used in the unselected population as the overall survival (OS) compared to placebo was limited and the efficacy is mainly driven by patients with activating *EGFR* driver mutations [1,2]. EGFR is a transmembrane tyrosine kinase protein receptor binding ligands of the EGF family, which activates several intracellular signaling cascades and is commonly expressed in NSCLC [3].

Preclinical models have shown that combination therapy of erlotinib and docetaxel with schedule dependent separation, results in additive apoptosis regardless of *EGFR* and Kirsten rat sarcoma viral oncogene homolog (*KRAS*) mutational status [4,5]. Several phase II studies have explored this combination hereafter [6–9].

In a previous randomized phase II study (NVALT-10), we showed improved OS in advanced relapsed NSQ- NSCLC patients treated with a combination of chemotherapy plus intercalated erlotinib compared to erlotinib monotherapy [10]. Pemetrexed was used as chemotherapy backbone in the non-squamous population and docetaxel in the squamous population. However, pemetrexed has moved to treatment in first line setting. Therefore the combination of the improved outcome shown in the NVALT-10 study and the pre-clinical evidence of additive effect of erlotinib and docetaxel led to the design of the NVALT-18 study.

The current NVALT-18 study (NCT0277500) was designed to investigate the efficacy of docetaxel with intercalated erlotinib compared to standard docetaxel monotherapy in patients with relapsed (*EGFR* and Anaplastic Lymphoma Kinase (*ALK*) wild type (WT)) NSQ-NSCLC. The study was ended prematurely due to slow accrual.

2. Material and methods

2.1. Study design

The NVALT-18 study is a prospective multicenter randomized open label phase III trial (NCT02775006). The protocol (see [Supplementary data](#)) was reviewed and approved by the Netherlands Cancer Institute (Antoni van Leeuwenhoek) medical ethical committee, written informed consent was obtained from all patients before randomization. Patients were followed until death or loss to follow up.

2.2. Study population

Patients were recruited at 12 sites in The Netherlands ([Supplementary Fig. S1](#)) between October 2016 and April 2018. Eligibility criteria included relapse of non-squamous cell (*EGFR* and *ALK* WT) NSCLC after platinum-based chemotherapy and/or checkpoint inhibitor, WHO performance status 0–1, adequate organ function and measurable disease according to Response Evaluation Criteria in Solid Tumours version 1.1 (RECIST v1.1) [11]. Presence of brain metastases was allowed provided cranial irradiation was completed more than 4 weeks before inclusion and steroid treatment had been stopped for at least 2 weeks before study inclusion. More details on in- and exclusion criteria are available in the [Supplementary Data](#).

Patients were stratified for WHO performance score (0 versus 1), previous immunotherapy (yes versus no) and treatment free interval after platinum-based therapy (<6 months versus greater than 6 months)

and randomized by a centralized computer randomization system (TENALEA) to open-label treatment.

2.3. Study treatment

Patients were randomized 1:1 to the control arm (A): docetaxel 75 mg/m² administered intravenously on day 1 every 21 days, or the experimental arm (B): docetaxel 75 mg/m² on day 1 administered intravenously plus erlotinib 150 mg/day on day 2–16 orally every 21 days. Treatment was continued until progression of disease, unacceptable toxicity or patient refusal.

2.4. Assessments

Patients were assessed before each cycle of treatment. Computed tomography of the chest and upper abdomen was scheduled every 6 weeks during treatment, and response was evaluated by RECIST v1.1 [11].

All adverse events (AE) equal to or exceeding Common Toxicity Criteria (CTC) version 4.03 grade 3, interstitial lung disease of any degree and all Serious Adverse Events (SAEs) were reported. The primary outcome measure was PFS, defined as the time from randomization to progression or death. Secondary endpoints were response rate, duration of response, OS (defined as time from randomization to death), and toxicity.

2.5. Statistical analysis

The intended number of inclusions was 230 with a preplanned interim analysis at 80 events.

Assuming a median time-to-event of 3 months in the control group and a hazard ratio (HR) of 0.67 in favor of combination therapy, performing the final analysis after observing 198 events would yield 80% power to show combination therapy superior at either analysis at a two-sided overall confidence level of 95%.

The (asymmetric) stopping boundaries for the interim analysis were based on the spending function of Hwang-Shih-DeCani with $\gamma = -4$ for both alpha and beta spending. With a single interim at 80 events this corresponds to stopping for efficacy when the observed HR is below 0.52 and stopping for futility when the observed HR is above 1.09.

Both PFS and OS were estimated by the Kaplan-Meier method and compared between arms by the log-rank test and by means of Cox proportional hazard models (R version 3.6, R Foundation for Statistical Computing, Vienna, Austria).

3. Results

3.1. Patient characteristics

Between October 2016 and April 2018 a total of 45 patients were randomized and received treatment in the control arm ($N = 23$) or the experimental arm ($N = 22$). The study terminated prematurely due to slow accrual. As docetaxel shifted from second to third line treatment after approval of second line immune checkpoint inhibitors the study was amended on 22nd February 2016 to allow inclusion of patients who were pretreated with second line immunotherapy. Nevertheless this had negative impact on our expected inclusion rate and in practice also on the number of available patients, as less patients receive treatment in a subsequent therapy line as the disease progresses in time. Baseline characteristics are displayed in [Table 1](#) and [Supplementary Table S1](#). Thirty patients (67%), 15 patients in each arm, were pretreated with second line immunotherapy. At time of database lock on 16th May 2019 the median follow up was 16 months (95% confidence interval (CI) 11.5 – NR).

Table 1
Patient characteristics.

	Control arm (A): Docetaxel monotherapy (N = 23)	Experimental arm (B): Docetaxel + erlotinib (N = 22)	All (N = 45)
Gender (%)			
Male	8 (35)	11 (50)	19 (42)
Female	15 (65)	11 (50)	26 (58)
WHO PS			
0	9 (39)	10 (45)	19 (42)
1	14 (61)	12 (55)	26 (58)
Smoking status			
Never	1 (4)	2 (9)	3 (7)
Former	18 (82)	15 (68)	33 (75)
Current	3 (14)	5 (23)	8 (18)
Histology			
Adenocarcinoma	23 (100)	19 (86)	42 (93)
Large cell carcinoma (NOS)	0	2 (9)	2 (4)
Neuro-endocrine (LCNEC)	0	1 (5)	1 (2)
Previous chemotherapy			
Yes	23 (100)	22 (100)	45 (100)
No	0 (0)	0 (0)	0 (0)
Previous ICI monotherapy			
Yes	15 (65)	15 (68)	30 (67)
No	8 (35)	7 (32)	15 (33)
Total previous lines of systemic treatment chemotherapy + ICI			
0	0	0	0
1	7 (30)	8 (36)	15 (33)
2	14 (61)	13 (59)	27 (60)
3	2 (9)	1 (5)	3 (7)
4	0	0	0
Previous radiotherapy			
Yes	16 (70)	12 (55)	28 (62)
No	7 (30)	10 (45)	17 (38)
Best response on study treatment			
CR	0 (0)	0 (0)	0 (0)
PR	3 (13)	2 (9)	5 (11)
SD	11 (48)	9 (41)	20 (44)
PD	7 (30)	10 (45)	17 (38)
Unknown	2 (9)	1 (5)	3 (7)

WHO PS; World Health Organization Performance Score, NOS; not otherwise specified, LCNEC; large cell neuro-endocrine carcinoma, ICI; immune checkpoint inhibitor, CR; complete response, PR; partial response, SD; stable disease, PD; progressive disease.

3.2. Progression free survival

At final analysis all patients had developed disease progression. In the docetaxel monotherapy control arm (A) median PFS was 4 months (95% CI: 1.5–7.1 months). In the experimental docetaxel with intercalated erlotinib arm (B) median PFS was 1.9 months (95% CI 1.4–3.5 months), adjusted hazard ratio (HR) 2.51 (95% CI: 1.16–5.43), $p = 0.01$ (Fig. 1A).

3.3. Statistical evaluation primary endpoint

Although the data refute the Null hypothesis (in the opposite direction from what was expected at the beginning of the trial) the decision to stop the trial was made before looking at the data and hence independent of this outcome. Simulations show that had we continued the trial to the point of the first preplanned interim analysis, the study would in all probability have been stopped at that time. Under assumption of the Null hypothesis (but given the results in the first 45 patients) the probability of crossing the stopping-for-futility boundary at the first interim analysis is 76%. Under the assumption that OS in the subsequent patients would follow the same distributions (in each arm) as seen in the first 45 patients, this probably would even be over 99%.

3.4. Tumor response

Objective response rate (best confirmed response complete or partial response) was 13% ($N = 3$) in the control arm (A) and 9% ($N = 2$) in the erlotinib plus docetaxel experimental arm (B), see Table 1. Durations of the tumor responses for these 3 patients in arm A were 14, 19 and 40 weeks, and in arm B 8 and 25 weeks, respectively.

3.5. Overall survival

Median OS from randomization was 10.6 months (95% CI: 7.0–8.6 months) in the control arm and only 4.7 months (95% CI: 3.2–8.6 months) in the experimental arm, adjusted HR 3.67 (95% CI: 1.46–9.27), $p = 0.004$, see Fig. 1B. The one year survival rate was 43% (95% CI: 26% – 74%) in the control monotherapy arm and 14% (95% CI: 5% – 39%) in the experimental arm.

3.6. Toxicity

In the control arm 6 patients (26%) experienced toxicity \geq CTCAE grade 3 compared to 17 patients (77%) in the experimental arm ($p = 0.0009$), mainly consisting of gastrointestinal symptoms and leukopenia. There were no CTCAE grade 5 AEs reported in this study.

There was one case of possible pneumonitis in a patient with pulmonary infection in the control arm (A) grade 3, treated with intravenously cefuroxime and prednisolone. The patient had a full recovery.

Toxicity is summarized in Table 2.

3.7. Treatment delivery

The median number of docetaxel courses was 2 (range 1 – 21) in the full study cohort: median 3 (range 1 – 21) in the control arm and median 2 (range 1 – 10) in the experimental arm. Patients received more than 6 cycles of therapy in 5 cases (22%) in the control arm and 2 cases (9%) in the experimental arm.

In 26 courses in 16 patients administration of docetaxel was modified, i.e.. reduced or delayed. A total of 16 modifications was due to adverse events; 4 events in $N = 4$ in the control arm and 12 events in $N = 9$ in the experimental arm. In 3 patients (control arm $N = 1$, experimental arm $N = 2$) an AE led to discontinuation of docetaxel treatment without progression of disease at that time point.

In the experimental arm the erlotinib administration was modified in 13 out of 22 patients. In 4 patients the daily dose was reduced to 100 mg and in 1 patient further reduced to 50 mg because of non-hematological AEs. The intercalated scheme was stopped earlier or interrupted in 9 patients; twice because of a hematological AE, in 7 patients because of a non-hematological AE and once on request of the patient. In 4 patients a cycle was postponed, once on request of the patient, otherwise because of adverse events.




Fig. 1. Kaplan-Meier curves of PFS (Fig. 1A) and OS (Fig. 1B).

Table 2

Toxicity (related to treatment).

Adverse events (grade 3 & 4)	Control arm (A), N = 23 (%)	Experimental arm (B), N = 22 (%)	All (N = 45, (%))
Hematological			
Leukopenia	3 (13)	5 (23)	8 (18)
Neutropenia	1 (4)	2 (9)	3 (7)
Febrile neutropenia	1 (4)	4 (18)	5 (11)
Leukocytosis	0	1 (5)	1 (2)
General			
Malaise	0	1 (5)	1 (2)
Fatigue	1 (4)	0	1 (2)
Weight loss	1 (4)	1 (5)	2 (4)
Pain	0	2 (9)	2 (4)
Syncope	0	1 (5)	1 (2)
Infection	0	1 (5)	1 (2)
Sepsis	0	2 (9)	2 (4)
Gastrointestinal disorder			
Abdominal pain	0	1 (5)	1 (2)
Diarrhea	0	2 (9)	2 (4)
Dysphagia	0	1 (5)	1 (2)
Oral mucositis	0	2 (9)	2 (4)
Nausea	0	1 (5)	1 (2)
Bilirubin increased	0	1 (5)	1 (2)
Vomiting	0	1 (5)	1 (2)
Pulmonary			
Respiratory failure	0	1 (5)	1 (2)
Dyspnea	1 (4)	0	1 (2)
Other			
Acute kidney injury	1 (4)	0	1 (2)
Palmar-plantar erythrodysesthesia syndrome	0	1 (5)	1 (2)
Pruritus	0	1 (5)	1 (2)

4. Discussion

Our hypothesis that a schedule dependent combination of docetaxel and intercalated erlotinib therapy is superior to docetaxel monotherapy was based on data from preclinical research and the results of the phase II NVALT-10 study [4,5,10]. However the data reported here suggest the contrary as the primary endpoint (PFS) was significantly shorter in the experimental arm than in the control arm. In addition, the secondary endpoint OS was significantly shortened in the experimental arm. Meanwhile toxicity was worse in the combination arm.

An antagonistic phenomenon could be anticipated when the two drugs are given concomitantly as cell cycle arrest in G1 due to the cytostatic effect of the EGFR-TKI might prevent the cytotoxic effect of docetaxel in the S and G2/M phase [4,5]. However, in vitro exploration of dose scheduling showed an additional effect of cell proliferation-

inhibition and apoptosis when erlotinib was administered after docetaxel [4,5]. An intercalated scheme of chemotherapy on day 1 with EGFR-TKI on day 2–16 in a 21 day cycle was therefore proposed as an optimal trial design. In a phase I/II trial the intercalated scheme of docetaxel and erlotinib was feasible and tolerable [6]. However, reports of phase II trials show opposite results. One trial showed no additional effect of the combination therapy in 147 randomized patients [7]. On the other hand, another study reported improved PFS, OS and disease control rate in the combination arm in 68 randomized patients [8]. Another phase II study conducted in male patients with squamous NSCLC was ended prematurely and showed no improvement in PFS at 6 months [9]. The most important differences between these studies and our study are the continuation treatment (erlotinib versus docetaxel plus intercalated erlotinib) and the difference in mutational status. While patients in the NVALT-18 were *EGFR*-WT, the other studies contained high levels of unknown mutational status which could explain the higher response rates and better outcomes. This is supported by the plasma analysis on a phase I/II trial where activating *EGFR* mutations detected in plasma were significantly associated with better outcomes [12]. A more recent single arm phase I/II trial included *EGFR*-WT patients and showed no improved overall response rate for the docetaxel and erlotinib combination [13]. The clinical trials on docetaxel with intercalated erlotinib are summarized in Table 3.

An important difference between cell line experiments and clinical trials in patients is the recurrence of drug administration in cycles. Whereas cell lines typically only receive 1 cycle of ‘therapy’ before measurements, patients are treated with several cycles of treatment. Possibly the remaining circulating erlotinib still has an antagonistic effect on the cytotoxic action of docetaxel after the first cycle. In the NVALT-10 study, erlotinib concentrations were measured in a subgroup of patients on day 22 prior to chemotherapy administration (and after 5 days of erlotinib interruption) [10]. Although the plasma levels of erlotinib did not reach therapeutic levels, the drug was still detectable in 12 out of 25 patients with a mean concentration of 79 ng/mL (SD 120 ng/mL) [10]. Enduring detection of erlotinib concentrations in tissue specimens after resection in a neoadjuvant setting up to 13 days after the last administration was reported earlier [14]. The mean lung tumor tissue erlotinib levels were 149 ng/g (SD 153 ng/g) after a mean of 7 days (SD 4.9 days) between last erlotinib intake and surgery. We hypothesize that erlotinib could still have activity in the intracellular compartment diminishing the cytotoxic effect of the chemotherapy after the 5 day washout period in our study, and a longer washout period could be necessary to overcome the antagonistic effect. Unfortunately we were unable to collect adequate samples for a preplanned pharmacokinetic analysis.

More adverse events equal to or exceeding CTC grade 3 were

Table 3
Clinical trials on docetaxel with intercalated erlotinib.

Study	Phase	Patient population	EGFR Status	Arms	Cycles	Maintenance	N=	ORR	PFS (months)	OS (months)
Sangha et al, 2011 [8]	I/II	Solid tumors/ NSCLC, any treatment line	unknown	IA docetaxel 70–75 mg/m2 every 21 days, erlotinib day 2,9 and 16 (600–1000 mg)	6	E	17 (10 NSCLC)	NA	NA	NA
				IB docetaxel 70–75 mg/m2 every 21 days, erlotinib days 2–16 (150–300 mg)	6	E	25 (12 NSCLC)	NA	NA	NA
				II docetaxel 70–75 mg/m2 every 21 days, erlotinib days 2–16 (150–300 mg)	6	E	39	28.20%	4.1	18.2
Auliac et al, 2014 [9]	II	NSCLC, second line	WT 68%, unknown 32%	C docetaxel 75 mg/m2 every 21 days	NA	D	74	6.6%	2.5	8.3
				E docetaxel 75 mg/m2 every 21 days, erlotinib 150 mg days 2–16	NA	DE	73	12.30%	2.2	6.5
Juan et al, 2015 [10]	II	NSCLC, second line	M 3%, WT 14%, unknown 83%	C erlotinib 150 mg/d continuously	NA	E	35	9%	2.1	5.2
				E docetaxel 75 mg/m2 every 21 days, erlotinib 150 mg days 2–16	4	E	33	3%	3.0	7.5
Gridelli et al, 2016 [11]	II	Male SQ-NSCLC, second line	unknown	C erlotinib 150 mg/d continuously	NA	E	36	2.8%	2.3	5.6
				E docetaxel 75 mg/m2 every 21 days, erlotinib 150 mg days 2–16	4	E	38	8.1%	2.8	8.9
Kimura et al, 2019 [13]	I/II	NSCLC, second line, EGFR-WT	WT	I docetaxel 60 mg/m2 every 21 days, erlotinib 150 mg days 2–16	NA	DE	12	NA	NA	NA
				II docetaxel 60 mg/m2 every 21 days, erlotinib 150 mg days 2–16	NA	DE	46	17.10%	3.5	11.3
Steendam et al, 2021	III	NSQ-NSCLC, second (or >) line, EGFR/ALK WT	WT	C docetaxel 75 mg/m2 every 21 days	NA	D	23	13%	4.0	10.6
				E docetaxel 75 mg/m2 every 21 days, erlotinib 150 mg days 2–16	NA	DE	22	9%	1.9	4.7

NSCLC, non-small cell lung cancer; SQ, squamous; NSQ, non-squamous; EGFR, Epidermal Growth Factor Receptor; WT, wild-type; M, mutated; N, number; E, experimental; E-I/E-II, experimental phase I/II; C, control; D, docetaxel; E, erlotinib; DE, docetaxel plus intercalated erlotinib; ORR, objective response rate; PFS, progression free survival; OS, overall survival; NA, not applicable.

reported in the docetaxel plus erlotinib arm. In addition, an earlier study reported a clinically relevant pharmacokinetic interaction between docetaxel and the TKI pazopanib, leading to a more than 50% increased systemic exposure to docetaxel [15]. Although we did not measure docetaxel concentrations in the NVALT-18 study, we cannot rule out that docetaxel levels increased due to erlotinib leading to more toxicity in the combination arm.

A limitation of our study was the open label design and lack of a double-blind experiment in this setting. Furthermore we did not include our prespecified sample size (as described in the study protocol in [supplementary data](#)).

To our knowledge this is the first study to report a clinically relevant inferior outcome in the experimental arm by intercalating erlotinib with docetaxel over docetaxel as standard treatment in EGFR-WT patients with NSQ-NSCLC. Earlier phase II trials reported no significant differences in outcome in control and experimental arms [7–9]. These trials did not reveal a detrimental effect of the combination therapy. However opposed to our study, the maintenance therapy consisted only of erlotinib monotherapy and not of a combination with docetaxel and patients were not selected on EGFR-WT status.

Our results therefore do not support the further exploration or implementation of docetaxel plus intercalated erlotinib treatment.

5. Conclusion

These data strongly discourage the clinical use or the further investigation of the docetaxel plus intercalated erlotinib regimen in (EGFR

and ALK WT) NSQ-NSCLC. Whether these data may be extrapolated to other EGFR-TKIs and/or other taxanes is currently unknown, but caution on adverse outcomes is strongly advised.

Declaration of Competing Interest

The authors declare that they have no known competing financial interests or personal relationships that could have appeared to influence the work reported in this paper.

Acknowledgements

We thank all patients and their families, and all the colleagues at the participating centers for their contributions to the NVALT-18 trial.

Funding

This work was supported by The Dutch Cancer Society (Grant number EMCR-2015-8059). The funding source had no involvement in the conduct of the research or the preparation of the article.

Disclosures

CS reports advisory board honorarium from Boehringer Ingelheim, grants (to institution) from AstraZeneca, other (hospitality/symposium) from Roche and Lilly, outside the submitted work. SK reports personal fees from Roche, outside the submitted work. HG reports fees (to

institution) from Lilly, other from Merck, Novartis, BMS, AbbVie, outside the submitted work. AD reports personal fees from Roche, Eli Lilly, Boehringer Ingelheim, Pfizer, BMS, Novartis, Takeda, Pharmamar, non-financial support from Abbvie, grants from BMS and Amgen, outside the submitted work.

RM reports grants from Astellas, Bayer, Boehringer-Ingelheim, Cristal Therapeutics, Pamgene, Pfizer, Prostatek, Roche, grants and personal fees from Novartis and Servier, outside the submitted work. JA reports personal fees and non-financial support from MSD, personal fees from BMS, Boehringer Ingelheim, Amphera, Eli-Lilly, Takeda, Bayer, Roche and AstraZeneca, outside the submitted work. In addition, JA has a patent allogenic tumor cell lysate licensed to Amphera, a patent combination immunotherapy in cancer pending, and a patent biomarker for immunotherapy pending. All remaining authors have declared no conflicts of interest.

Appendix A. Supplementary data

Supplementary data to this article can be found online at <https://doi.org/10.1016/j.lungcan.2021.08.002>.

References

- [1] D. Planchard, S. Popat, K. Kerr, S. Novello, E.F. Smit, C. Faivre-Finn, T.S. Mok, M. Reck, P.E. Van Schil, M.D. Hellmann, S. Peters, Metastatic non-small cell lung cancer: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up, *Ann. Oncol.* 29 (2018) iv192–iv237.
- [2] F.A. Shepherd, J. Rodrigues Pereira, T. Ciuleanu, E.H. Tan, V. Hirsh, S. Thongprasert, D. Campos, S. Maoleekoonpiroj, M. Smylie, R. Martins, M. van Kooten, M. Dediu, B. Findlay, D. Tu, D. Johnston, A. Bezjak, G. Clark, P. Santabarbara, L. Seymour, Erlotinib in previously treated non-small-cell lung cancer, *N. Engl. J. Med.* 353 (2) (2005) 123–132.
- [3] J. Mendelsohn, J. Baselga, Epidermal growth factor receptor targeting in cancer, *Semin. Oncol.* 33 (4) (2006) 369–385.
- [4] C.M. Mahaffey, A.M. Davies, J.P.N. Lara, B. Pryde, W. Holland, P.C. Mack, P. H. Gumerlock, D.R. Gandara, Schedule-dependent apoptosis in K-ras mutant non-small-cell lung cancer cell lines treated with docetaxel and erlotinib: rationale for pharmacodynamic separation, *Clin. Lung Cancer.* 8 (9) (2007) 548–553.
- [5] K. Furugaki, T. Iwai, M. Shirane, K. Kondoh, Y. Moriya, K. Mori, Schedule-dependent antitumor activity of the combination with erlotinib and docetaxel in human non-small cell lung cancer cells with EGFR mutation, KRAS mutation or both wild-type EGFR and KRAS, *Oncol. Rep.* 24 (2010) 1141–1146.
- [6] R. Sangha, A.M. Davies, P.N. Lara, P.C. Mack, L.A. Beckett, P.J. Hesketh, D. Lau, T. Li, N. Perkins, D.R. Gandara, Intercalated erlotinib-docetaxel dosing schedules designed to achieve pharmacodynamic separation: results of a phase I/II trial, *J. Thorac. Oncol.* 6 (12) (2011) 2112–2119.
- [7] J.B. Auliac, C. Chouaid, L. Greiller, I. Monnet, H. Le Caer, L. Falchero, R. Corre, R. Descourt, S. Bota, H. Berard, R. Schott, A. Bizieux, P. Fournel, A. Labrunie, B. Marin, A. Vergnenegre, Randomized open-label non-comparative multicenter phase II trial of sequential erlotinib and docetaxel versus docetaxel alone in patients with non-small-cell lung cancer after failure of first-line chemotherapy: GFPC 10.02 study, *Lung Cancer.* 85 (3) (2014) 415–419.
- [8] O. Juan, F. Aparisi, A. Sanchez-Hernandez, J. Munoz-Langa, G. Esquerdo, J. Garcia-Sanchez, et al., Intercalated Dosing Schedule of Erlotinib and Docetaxel as a Therapeutic Strategy to Avoid Antagonism and Optimize Its Benefits in Advanced Non-Small-Cell Lung Cancer. A Randomized Phase II Clinical Trial, *Clin. Lung Cancer.* 16 (2015) 193–199.
- [9] C. Gridelli, A. Chella, G. Valmadre, G. Allegrini, M. Brighenti, P. Bidoli, et al., Second-line Erlotinib or Intermittent Erlotinib plus Docetaxel in Male Ex-smokers with Squamous NSCLC: The TALISMAN Randomized Trial, *Anticancer Res.* 36 (12) (2016) 6535–6540.
- [10] J.G. Aerts, H. Codrington, N.A.G. Lankheet, S. Burgers, B. Biesma, A.-M.-C. Dingemans, A.D. Vincent, O. Dalesio, H.J.M. Groen, E.F. Smit, A randomized phase II study comparing erlotinib versus erlotinib with alternating chemotherapy in relapsed non-small-cell lung cancer patients: the NVALT-10 study, *Ann. Oncol.* 24 (11) (2013) 2860–2865.
- [11] E.A. Eisenhauer, P. Therasse, J. Bogaerts, L.H. Schwartz, D. Sargent, R. Ford, J. Dancey, S. Arbuck, S. Gwyther, M. Mooney, L. Rubinstein, L. Shankar, L. Dodd, R. Kaplan, D. Lacombe, J. Verweij, New response evaluation criteria in solid tumours: revised RECIST guideline (version 1.1), *Eur. J. Cancer.* 45 (2) (2009) 228–247.
- [12] P.C. Mack, W.S. Holland, R.A. Burich, R. Sangha, L.J. Solis, Y. Li, L.A. Beckett, P. N. Lara, A.M. Davies, D.R. Gandara, EGFR mutations detected in plasma are associated with patient outcomes in erlotinib plus docetaxel-treated non-small cell lung cancer, *J. Thorac. Oncol.* 4 (12) (2009) 1466–1472.
- [13] T. Kimura, T. Kawaguchi, Y. Chiba, H. Yoshioka, K. Watanabe, T. Kijima, et al., Phase I/II study of intermittent erlotinib in combination with docetaxel in patients with recurrent non-small cell lung cancer (WJOG4708L), *Jpn. J. Clin. Oncol.* 49 (2019) 947–955.
- [14] N.A.G. Lankheet, E.E. Schaake, S.A. Burgers, R. van Pel, J.H. Beijnen, A.D. R. Huitema, H. Klomp, Concentrations of Erlotinib in Tumor Tissue and Plasma in Non-Small-Cell Lung Cancer Patients After Neoadjuvant Therapy, *Clin. Lung Cancer.* 16 (4) (2015) 320–324.
- [15] P. Hamberg, R.H.J. Mathijssen, P. de Bruijn, C. Leonowens, D. van der Biessen, F.A. L.M. Eskens, S. Sleijfer, J. Verweij, M.J.A. de Jonge, Impact of pazopanib on docetaxel exposure: results of a phase I combination study with two different docetaxel schedules, *Cancer Chemother Pharmacol.* 75 (2) (2015) 365–371.